GOVERNMENT OF INDIA
CHEMICALS AND FERTILIZERS
LOK SABHA

UNSTARRED QUESTION NO:290
ANSWERED ON:09.08.2012
FUND FOR FINANCING NEW DRUG DISCOVERY PROJECTS
Rani Killi Krupa

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) the allocation of funds on R & D and action taken to streamline the research activities in the country during the last three years;

(b) whether the Government: proposes to create a fund to finance new drug discovery projects t:o make India a leader in drug discovery;

(c) if so, the details thereof;

(d) whether the Government is proposing to offer incentives to domestic as well as multinational drug makers to encourage new drug discovery in the country; and

(e) if so, the details thereof?

Answer

MINISTER OF STATE (INDEPENDENT CHARGE) IN THE MINISTRY OF STATISTICS AND PROGRAMME IMPLEMENTATION AND MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI SRIKAMT KUMAR JENA).

(a): As per available information, funds have been allocated for R&D by the Departments of the Government of India during the last three years, are as follows:

Name of the Department	(Rs. in crores)
(i) Department of Science & Technology	165.69
(ii) Department of Bio-technology	66.89
(iii) Council of Scientific and Industrial Research	254.81
(iv) Indian Council of Medical Research	24.00
(v) Department of Pharmaceuticals	57.03

In the Report of the Working Group on Drugs and Pharmaceuticals Industry for the 12m Plan, the following proposals relating to R&D have been included:-

S.NO.	Scheme	Brief description	Outlay (Rs. in crores)

1. Setting up of one National and five Regional Formulation Development and Manufacturing standards training centres	Scheme to set up Formulation development centres to tap the patent cliff opportunity and become global leader in Generics and Bio-similars	160
2. Setting up of National Centre for Phyto-pharma development	Major capital expenditure of about Rs 100 crores being met from Ministry for Development of North East Region (DONER). Present allocation sought for initial years operation as per advice from DONER	20
3. Good Practices Laboratory (GLP)/Good Clinical Practices (GCP) Animal House Lab Schemes	For setting up of GLP compliant Laboratop/, (GLP) GCF compliant Lab and a Animal House Lab on Public Private Partnership (PPP) basis	50
4. Continuing R&D schemes at National Institute of Pharmaceutical Education and Research (NIPER), Mohali	NIPER, Mohali is presently implementing a number of projects in R&D for various Pharma areas like neglected diseases, infectious diseases, vector borne diseases, etc. In addition a number of projects are being implemented for Public health, Pharmacovigilance, Regulatory capacity building for academia and industry, etc.	50
5. New Scheme at NIPER Mohali	R&D Centre for Biologicals and New Chemical Entities (NCEs) R&D Centre for New Drug Delivery System (NDDS), Setting up 20 new Incubators, Incentive Scheme for Contract Research Organization (CROs) Development for New, Drug Discovery Partnership with International Centres of Excellence	825
6. Pharma Venture Capital Fund	To consider investment of identified funds into a newly created specialised private equity/venture capital fund that undertakes R&D investments into companies in the pharmaceutical industry	500
7. Pharma Innovation and Infrastructure Development Initiative (PIIDI)	Develop technical and innovation capacity of Indian Pharma for manufacturing quality affordable medicines, develop International	2000

	competitiveness of the Indian Pharma so as to be the largest producer of generic medicines in the world. To make India a preferred destination for global initiatives in curing the world`s ailments specially the developing world in a value based manner.		
8.	At NIPER Hyderabad: Setting up National Centre for R&D in Bulk Drugs at NIPER Hyderabad	Build competitiveness through Innovation and Productivity efficiencies in the Active Pharmaceuticals Ingredient (API) industry. Also tap Generics opportunity and meet competition of China, etc.	56
9.	At NIPER Kolkata National Pharmaceutical Nanotechnology Centre	To be set up at NIPER Kolkata for development of Nano-materials from inorganic substrates for innovative drugs and drug delivery systems	50
10.	Setting up National and Regional BiosimiiarExpertise Centreson	To provide expert advice and assistance to industry regulatory issues pertaining to Clinical Trials, Testing and Approval process for Biosimilars - One national centre at Bangalore and 3 regional centres at Chandigarh, Hyderabad and Ahmedabad	60
11.	Setting up of a Industry focused Animal House	End to end services from Primates to small animals for pre-clinical drug development	100
12.	Support to Academia, Research Institutions and private sector for Extra Mural Research	For funding both academia individually,as an institution and private companies for targeted drug development including assistance for clinical trials.	100
13.	Support to Academia, Research Institutions and private sector for Extra Labs upgradation	For funding upgradation of labs in the private and government sector with sharing basis on 50-50 pattern for the lab upgradation for equipments deployed for drug development under specifically identifiable projects	10
14.	All NIPERs: International cooperation inR&D	To promote R&D in Commonwealth of Independent States (CIS) and developing countries for mutual	25

	advantages		
15.	Setting up National Centre for Medical Devices at NIPER Ahmedabad	Promoting indigenous R&D in Medical devices sector	50
	Total		4056

(b)to(e): In November 2011, M/s. Ernst & Young Private Limited (M/s E&Y), Gurgaon, has been given an assignment as Global Level Consultant for preparation of Detailed Project Report for developing India as a Drug Discovery & Pharma Innovation Hub 2020. The report is awaited.